Sign up for NPL updates
Sign up for NPL updates

NPL and UKRI investment for innovation in time resilience, dissemination and application.
Funding of up to £4.7 million available through joint initiative, call for applications now open.

COVID-19 response

Supporting vaccine development

SI-traceable reference materials for vaccines

There was a massive international effort to develop a COVID-19 vaccine, with over 150 candidates in clinical trials. Vaccines can show variability in their physical and biological properties, and manufacturers need to ensure performance consistency from development to batch release. To succeed in this, new reference materials based on prototype vaccine platforms are needed. In addition, effective management and tracing of viral pandemics requires reference materials to ensure accurate and reliable detection.

It is vital to formulate and validate suitable reference standards that exhibit the physical and biological properties of viruses and virus-like structures to benchmark the physicochemical and biological attributes of vaccines. In collaboration with the NHS, NPL set up an inter-comparison to validate virus-like particles using high resolution electron microscopy, so that they could be used as reference materials for the characterisation of vaccines and the diagnosis of viral diseases. 

NPL, with VAMAS and NIST, launched an international call for inter-laboratory comparisons, inviting proposals to characterise and validate materials and methods. This activity sits under the VAMAS TWA40 chaired by NPL.

NPL worked on the development of reference virus-like particles exhibiting nanoscale properties and characteristics suitable for accurate, differential measurements of cells, viruses and virus-like structures in clinical samples. The comparison studies helped improve repeatability and reproducibility of methods and materials, and where applicable, validated measurement results with traceability to the SI. These characteristics remain fundamental to ensuring the quality, approval and delivery of safe and effective vaccines and helped improve the repeatability and reproducibility of diagnostic methods.

If you would like to discuss further, please contact us.

Contact us

Impact during COVID-19

  • Led interlaboratory comparisons to accelerate support for vaccine development
  • Ensured SI-traceability to improve differential diagnostics of viruses
  • Developed reference materials for viral diagnostics and vaccine development

NPL has a broad range of related activities

Work with us

Our research and measurement solutions support innovation and product development. We work with companies to deliver business advantage and commercial success.
Contact our Customer Services team on +44 20 8943 7070